Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped down prior to trading on Wednesday . The stock had previously closed at $51.33, but opened at $48.14. Zealand Pharma A/S shares last traded at $48.14, with a volume of 118 shares trading hands.

Analyst Ratings Changes

Several research firms have commented on ZLDPF. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Finally, William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

The company’s fifty day simple moving average is $48.62 and its 200 day simple moving average is $64.63. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $3.40 billion, a P/E ratio of 3.47 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.53. The firm had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $19.69 million. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. As a group, sell-side analysts forecast that Zealand Pharma A/S will post 2.51 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.